Teva Pharmaceutical Industries Sees Unusually High Options Volume (NYSE:TEVA)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) saw some unusual options trading on Tuesday. Stock traders purchased 27,298 call options on the stock. This is an increase of approximately 82% compared to the typical volume of 14,998 call options.

Wall Street Analysts Forecast Growth

TEVA has been the topic of a number of recent analyst reports. Truist Financial boosted their price target on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, January 21st. Piper Sandler reissued an “overweight” rating and set a $41.00 target price (up from $40.00) on shares of Teva Pharmaceutical Industries in a research note on Wednesday, March 4th. The Goldman Sachs Group boosted their target price on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, February 9th. Finally, Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $37.67.

Insider Buying and Selling

In related news, insider Mark Sabag sold 62,102 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $30.14, for a total transaction of $1,871,754.28. Following the completion of the transaction, the insider directly owned 224,940 shares of the company’s stock, valued at $6,779,691.60. This trade represents a 21.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Placid Jover sold 14,150 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $448,130.50. Following the transaction, the insider directly owned 6,774 shares in the company, valued at $214,532.58. The trade was a 67.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 920,901 shares of company stock valued at $30,056,789 over the last three months. Insiders own 0.49% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Hedge funds and other institutional investors have recently modified their holdings of the company. AQR Capital Management LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 24.6% in the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock worth $368,000 after purchasing an additional 4,732 shares in the last quarter. Focus Partners Wealth increased its stake in Teva Pharmaceutical Industries by 4.5% during the 1st quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after purchasing an additional 1,739 shares in the last quarter. Creative Planning increased its stake in Teva Pharmaceutical Industries by 23.8% during the 2nd quarter. Creative Planning now owns 56,164 shares of the company’s stock valued at $941,000 after purchasing an additional 10,784 shares in the last quarter. Franklin Resources Inc. acquired a new position in Teva Pharmaceutical Industries during the second quarter worth $255,000. Finally, Rhumbline Advisers raised its holdings in Teva Pharmaceutical Industries by 2.3% during the second quarter. Rhumbline Advisers now owns 287,401 shares of the company’s stock worth $4,817,000 after buying an additional 6,339 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Up 0.5%

Teva Pharmaceutical Industries stock opened at $30.26 on Thursday. The company has a market capitalization of $34.79 billion, a PE ratio of 25.21, a PEG ratio of 10.15 and a beta of 0.76. Teva Pharmaceutical Industries has a 12-month low of $12.47 and a 12-month high of $37.35. The firm’s fifty day moving average is $32.22 and its 200 day moving average is $27.63. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The company had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. During the same period last year, the business posted $0.71 EPS. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, sell-side analysts predict that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.